Be the first to review this item
Memantine Canon (Memantin, Memantinum) - muscle relaxant central action.
Adamantane derivatives, the chemical structure and pharmacological properties similar to amantadine. Memantine blocks the NMDA glutamate-receptors (including those in the substantia nigra), thereby reducing the excessive stimulating effect on cortical neurons glutamatngh neostratum that develops against the backdrop of insufficient vydeleniyadofamina. At the moment, there is no reliable evidence base showing the drug's ability to slow or prevent the progressive course of the disease of Alzheimer's.
It enhances the effect of barbiturates, antipsychotics, levodopa, dopamine agonists receptors, anticholinergic agents, amantadine. It may change the effect of dantrolene and baclofen.
Individual hypersensitivity to the drug, pronounced renal dysfunction, pregnancy, breastfeeding.
Be wary appoint patients with thyrotoxicosis, epilepsy.
In patients with Alzheimer's disease at the stage of moderate to severe dementia usually impair the ability to drive vehicles and management of complex mechanisms.
Memantine may cause a change in the reaction rate, so patients receiving treatment on an outpatient basis, you should be particularly careful when driving or operating machinery.
Memantine Canon Inside, during a meal. Dosage is determined individually. Initiate therapy with the recommended destination minimally effective doses.
Adults with dementia during the 1st week of treatment - 5 mg / day, 2nd week - at a dose of 10 mg / day, the 3rd week - at a dose of 15-20 mg / day. If necessary, may further increase a weekly dose of 10 mg to achieve a daily dose - 30 mg.
The optimal dose is achieved gradually by increasing the dose every week.
Important notice- the outer box design may vary before prior notice!